ストックスクリーナーアプリを入手
25.22
0.72%
0.18
アフターアワーズ：
25.18
-0.04
-0.16%
前日終値:
$25.04
開ける：
$25.11
24時間の取引高:
61.90M
Relative Volume:
0.93
時価総額：
$143.39B
収益：
$62.79B
当期純損益:
$9.84B
株価収益率:
14.70
EPS:
1.7156
ネットキャッシュフロー:
$10.38B
1週間 パフォーマンス:
+0.56%
1か月 パフォーマンス:
+1.86%
6か月 パフォーマンス:
+8.15%
1年 パフォーマンス:
-1.68%
1日の値動き範囲:
$25.05
$25.47
1週間の範囲:
$24.28
$25.52
52週間の値動き範囲:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
PFE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.22 | 142.37B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,070.16 | 948.45B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.05 | 491.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.51 | 417.60B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.54 | 244.28B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.40 | 242.64B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors? - Yahoo Finance UK
Should FDA Approval of PADCEV Plus Keytruda Shift Pfizer's (PFE) Oncology Innovation Outlook? - simplywall.st
Which Is A Better Pick: Johnson & Johnson or Pfizer Stock? - Trefis
Guggenheim Raises Price Target for Pfizer (PFE) to $35 | PFE Sto - GuruFocus
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS) - GlobeNewswire Inc.
Guggenheim Adjusts Price Target on Pfizer to $35 From $33, Maintains Buy Rating - MarketScreener
14 Stocks Jim Cramer Recently Shed Light On - Insider Monkey
MCC STEM students and employees visit Pfizer - Lowell Sun
A Look at Pfizer's Valuation Following FDA Approval of PADCEV Combination Therapy for Bladder Cancer - simplywall.st
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon - Finviz
Pfizer Secures a Major Regulatory Win—How Will Its U.S. Drug Pricing Deal Shape 2026? - Smartkarma
Does Pfizer’s AI-Powered R&D Signal a New Opportunity for 2025? - Yahoo Finance
Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know - The Globe and Mail
Pfizer Inc. (PFE) Completes Significant Public Offering of Notes - GuruFocus
Pfizer completes $6 billion public notes offering across multiple maturities - Investing.com
Pfizer completes $6 billion public notes offering across multiple maturities By Investing.com - Investing.com India
Pfizer Sells $6 Billion of Notes - MarketScreener
Pfizer Completes $5 Billion Public Offering - TipRanks
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Why Are Shares of Pfizer Up Today? - Benzinga
Pfizer, Astellas Say FDA Approves Padcev-Keytruda Combo in Bladder Cancer - MarketScreener
Pfizer (PFE) Gains FDA Approval for New Bladder Cancer Treatment - GuruFocus
mRNA flu shot shows better results than traditional vaccine in trial - upi.com
Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025 - ts2.tech
Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant StrainsPfizer (NYSE:PFE) - Benzinga
New Trial Shows Pfizer’s mRNA Flu Shot Beats Traditional Flu Vaccine - Citizen Tribune
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
Medical Morphine Market Deep Research Report with Forecast - openPR.com
Necrotizing Fasciitis Market to Witness Remarkable Growth With - openPR.com
Amazon and Pfizer plunder $22bn on final approach to Thanksgiving - GlobalCapital
Pfizer (PFE) Agrees to $41.5 Million Settlement Over Drug Allega - GuruFocus
Is Pfizer's 6.9%-Yielding Dividend Still Safe? - The Globe and Mail
Pfizer scores a win for mRNA vaccines with influenza data - The Pharma Letter
Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too? - Barchart.com
HK-listed Hbm climbs to six-week high on licence deal with Pfizer - TradingView
Pfizer aims to seek oral obesity treatments worldwide following Metsera purchase – CEO - MSN
Pfizer: Is This Pharma Giant Finally A Bargain (NYSE:PFE) - Seeking Alpha
Pfizer, Tris Pharma Settle Texas ADHD Drug Case for $41.5 Million - MarketScreener
Pursuing the Next Breakthrough in Cancer Cachexia - Pfizer
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial - MyChesCo
Pfizer, Tris Pharma Reach $41.5M Settlement in Texas ADHD Drug Fraud Suit - USA Herald
Pfizer To Pay $41.5M To Settle Adulterated ADHD Drug Claims - Law360
Pfizer in $41.5 million settlement with Texas over ADHD drug for children - WKZO
Pfizer, Tris Pharma Reach $41.5 Million Settlement With Texas Over Alleged Adulterated ADHD Medicine - MarketScreener
Pfizer (PFE) and Tris Pharma Settle ADHD Drug Lawsuit for $41.5M - GuruFocus
Pfizer, Tris Pharma To Pay Texas $41.5 Million in ADHD Drug Suit - news.bloomberglaw.com
Jefferies 25: Pfizer Still Hungry For Anti-Obesity Deals After Metsera - Citeline News & Insights
Pfizer resolves Texas lawsuit over adulterated ADHD drug in $41.5M settlement - Seeking Alpha
Vitiligo Market Analysis and Forecasts 2025-2035 Featuring Abbvie, Incyte, Amgen, Pfizer, Clinuvel Pharmaceuticals, TWi Biotech, and Arcutis BiotherapeuticsResearchAndMarkets.com - The AI Journal
Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025 - ts2.tech
Pfizer CEO on plans to bring down drug prices - Yahoo Finance
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
5.58%
2.70%
大文字化:
|
ボリューム (24 時間):